Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
ASX:MYX
Price:
6.93 AUD
-2.39%
Market Closed
Updated:
Apr 27, 2024
Income Statement
Earnings Waterfall
Mayne Pharma Group Ltd
Mayne Pharma Group Ltd
|
Revenue
|
278.4m
AUD
|
|
Cost of Revenue
|
-89m
AUD
|
|
Gross Profit
|
189.5m
AUD
|
|
Operating Expenses
|
-286.9m
AUD
|
|
Operating Income
|
-97.4m
AUD
|
|
Other Expenses
|
-145.9m
AUD
|
|
Net Income
|
-243.3m
AUD
|
Income Statement
Mayne Pharma Group Ltd
Mayne Pharma Group Ltd
Currency: AUD
| Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Revenue |
343
N/A
|
158
-54%
|
62
-61%
|
190
+208%
|
278
+46%
|
|
| Gross Profit | ||||||
| Cost of Revenue |
(191)
|
(82)
|
(37)
|
(100)
|
(89)
|
|
| Gross Profit |
151
N/A
|
75
-50%
|
25
-67%
|
90
+265%
|
189
+110%
|
|
| Operating Income | ||||||
| Operating Expenses |
(169)
|
(131)
|
(167)
|
(256)
|
(287)
|
|
| Selling, General & Administrative |
(120)
|
(133)
|
(152)
|
(190)
|
(190)
|
|
| Research & Development |
(17)
|
(12)
|
(13)
|
(16)
|
(18)
|
|
| Depreciation & Amortization |
(56)
|
(48)
|
(39)
|
(57)
|
(63)
|
|
| Other Operating Expenses |
25
|
62
|
36
|
7
|
(16)
|
|
| Operating Income |
(17)
N/A
|
(56)
-225%
|
(142)
-154%
|
(165)
-17%
|
(97)
+41%
|
|
| Pre-Tax Income | ||||||
| Interest Income Expense |
(4)
|
(9)
|
(23)
|
(19)
|
(17)
|
|
| Non-Reccuring Items |
(97)
|
(81)
|
(44)
|
(85)
|
(63)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(119)
N/A
|
(146)
-23%
|
(208)
-43%
|
(270)
-30%
|
(178)
+34%
|
|
| Net Income | ||||||
| Tax Provision |
26
|
(75)
|
(59)
|
(48)
|
(81)
|
|
| Income from Continuing Operations |
(93)
|
(220)
|
(268)
|
(317)
|
(259)
|
|
| Income to Minority Interest |
0
|
11
|
10
|
0
|
(0)
|
|
| Net Income (Common) |
(78)
N/A
|
(281)
-263%
|
59
N/A
|
117
+98%
|
(243)
N/A
|
|
| EPS (Diluted) |
-0.95
N/A
|
-3.41
-259%
|
0.71
N/A
|
1.42
+100%
|
-3.02
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
